Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign

Amber Tong

Paul Schloesser

Associate Editor

For the past year or so, Covid-19 has dominated the narrative around AstraZeneca. And for good reason: The pharma giant has shipped 2.6 billion doses …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign

Amber Tong

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Pas­cal So­ri­ot: As­traZeneca 'on track' to hit big $40B goal, cap­ping years-long turn­around cam­paign

Associate Editor

Sign up to read this article for free.

Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign